LEGN News & Analysis
3 articles
Market Mood
Legend Biotech (LEGN) Stock Price Target Raised by UBS on NHL Outlook
UBS increased its price target for Legend Biotech (LEGN) reflecting a positive outlook on its NHL therapy development. No specific new price target was provided in the report. The adjustment signifies UBS's confidence in the market potential of LEGN's therapeutic advancements and could influence investor sentiment positively. This change might impact trading volumes as investors react to the report, indicating potential shifts in the stock's market dynamics.
Read More
Legend Biotech (LEGN) Stock Rating Reiterated as Buy by H.C. Wainwright
H.C. Wainwright has reaffirmed its stock rating for Legend Biotech (LEGN) as 'buy'. This determination reflects confidence in the company's growth potential and market position. The analyst noted key developments in the company's pipeline, though specific numbers or future projections were not provided. Such endorsements can influence investor perception and potentially impact the stock's trading volume positively.
Read More
Legend Biotech (LEGN) Reports $1.9B Sales for CARVYKTI in 2025
Legend Biotech Corporation (LEGN) announced financial results for 2025, achieving $1.9 billion in net trade sales from its CARVYKTI therapy, including ~$555 million in Q4. The company reported a collaboration revenue increase to $277.6 million in the final quarter. With over 10,000 patients treated and a global footprint expanding to 294 sites across 14 markets, LEGN is positioned for growth. Additionally, the company opened a new 31,000-square-foot R&D facility in Philadelphia to support its pipeline advancements.
Read More